The Role of the PI3K/AKT2 Pathway in Anti-Estrogen Resistant Breast Cancer

Loading...
Thumbnail Image
Authors
Busch, Stephanie M.
Issue Date
2004
Type
Presentation
Language
en_US
Keywords
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
Breast cancer is one of the most common forms of cancer in women in the western world. Estrogen has been shown to play a key role in the development and progression of breast cancer with 2/3 of tumors expressing estrogen receptor-α (ERα). Under prolonged exposure to endogenous estrogens, breast tumors develop. Over the past two decades, Tamoxifen has been the most effective anti-estrogen therapy in the treatment of ERα-positive breast cancer (Osbourne et al., 1998). Unfortunately, patients eventually acquire resistance to Tamoxifen within four to eight years. Previous research has shown activation of PI3K/AKT2 and Ras/MAPK signaling pathways lead to tamoxifen resistance (Atanaskova, N et al., 2002). The purpose of this project is to establish the role of the PI3K/AKT2 pathway and its downstream signaling molecules, specifically mTOR, in anti-estrogen treatment. Inhibition of mTOR signaling by rapamycin was done to determine if p70 S6 Kinase and 4E-BP1 activation could be inhibited. In turn, cell cycle progression and tumor growth would, in theory, stop; therefore, tamoxifen resistance could be reversed in tumor cells that overexpress activated AKT2. Western blot analyses were conducted to visualize phosphorylated levels of 4E-BP1 and p70 S6 Kinase in EGFR/MCF-7 and MCF-7 cells. Overall, this research has implications for improving estrogen-mediated breast cancer treatment with Tamoxifen.
Description
1 broadside : ill.
Diebold Scholar
Citation
Publisher
Kalamazoo College
License
Journal
Volume
Issue
PubMed ID
DOI
ISSN
EISSN